Vicki buys RARE 44.75: Ultragenyx Announces Results From Phase 1/2 Study Of KRN23 In X-linked Hypophosphatemia In Adults
NOVATO, Calif., June 24, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of results from a .. ...
25 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home